US DHHS orders additional flu vaccine as pandemic precaution
Three major manufacturers of vaccines have been awarded contracts by the USA's Department of Health and Human Services for additional supplies of antivirals for use in the event of an influenza pandemic.
The DHHS' Secretary Michael Leavitt announced the award, worth $199.5 million, as part of the US federal government's program against a potential mutated H5N1 avian influenza virus threat.
The three companies receiving the contracts were: Sanofi Pasteur, the vaccines division of France's Sanofi-Aventis, (3.7 million doses at $117.9 million), Switzerland's Novartis (800,000 at $41.0 million) and the UK's GlaxoSmithKline (800,000 at $40.6 million).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze